Mein Warenkorb

CLEC4C

CLEC4C Molekülinformation

Englischer NameC-Type lectin domain family 4 member CAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel9Target-AliasDLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Englischer NameC-Type lectin domain family 4 member C
Target-AliasDLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel9
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical

CLEC4C Produktliste

  • Attribut

    Protein (6)

  • Produktbibliothek

    Online (6)

  • Spezies

    Human (3)Cynomolgus (3)

  • Etikett

    Fc Tag (2)His Tag (2)His Tag & Avi Tag (2)

  • Marker

    Unconjugated (4)Biotin-labeled (2)

CLEC4C Molekülhintergrund

CLEC4C (C-type lectin domain family 4 member C), also known as BDCA2, CLECSF11, CLECSF7, DLEC and CD303. Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cell. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.

CLEC4C Molekülalias

DLEC,CLEC4C,BDCA-2,CD303,CLECSF11,CLECSF7, HECL

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
LitifilimabBIIB-059Phase 3 ClinicalBiogen IncLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
SSGJ-626SSGJ-626; 626Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
DB-2304DB-2304Phase 2 ClinicalDuality Biologics (Suzhou) Co LtdAutoimmune Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
ANB-101CBS-004; ANB101Phase 1 ClinicalCapella Bioscience LtdInflammation; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Scleroderma, Systemic
Details
BCD-256BCD-256Phase 1 ClinicalBIOCAD JSCLupus Erythematosus, Systemic
Details
GB-19GB-19; GB19Phase 1 ClinicalShandong Kexing Bio-Products Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
Recombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian)Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
HC-022HC-022; HC022Phase 1 ClinicalShanghai Hongcheng Pharmaceutical Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
LBL-047DNTH-212; LBL-047; DNTH212Phase 1 ClinicalNanjing Leadsbiolabs Co LtdAutoimmune Diseases; Lupus Erythematosus, Systemic
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns